窦女士的体验并非个例。跨省异地就医直接结算，正在给越来越多的参保人带来实实在在的便利。 "以前报销需要拿着一摞发票回老家，现在刷医保卡就能直接在医院报销，方便多了！"河南居民窦 女士退休后长期随子女居住在北京，随着医保跨省异地就医直接结算的推开，以前往往需要几周的报销 流程，现在几秒钟就可以完成，还不用自己垫付资金。 来自河北廊坊的参保居民刘女士是这项政策的受益者。患有强直性脊柱炎的她长期在北京进行治 疗，治疗所需的司库奇尤单抗注射液每支870元，一次需要4支，通过门诊慢特病跨省异地就医直接结 算，她可以使用医保基金支付1519.2元。"医保服务太贴心了，我再也不用带着发票回河北了！" 最新数据显示，截至2025年第一季度末，门诊慢特病跨省异地就医直接结算定点医疗机构数量为 7.4万家，较2024年年底增长2.62%。 动动手指，医保服务高效办。 国家医保服务平台App异地备案和线上查询等功能不断完善，支持线上查询异地联网定点医药机 构、医保服务热线、个人报销费用等信息；京津冀实现"一卡通行"，无需办理异地就医备案手续，即可 享受医保报销待遇……更多探索正在进行，让老百姓异地就医更方便。 国家医保局副局长黄华 ...

新华社北京8月3日电 题：动动手指就搞定——医保跨省异地就医为参保人保驾护航 新华社记者徐鹏航、彭韵佳 "以前报销需要拿着一摞发票回老家，现在刷医保卡就能直接在医院报销，方便多了！"河南居民窦 女士退休后长期随子女居住在北京，随着医保跨省异地就医直接结算的推开，以前往往需要几周的报销 流程，现在几秒钟就可以完成，还不用自己垫付资金。 窦女士的体验并非个例。跨省异地就医直接结算，正在给越来越多的参保人带来实实在在的便利。 跨省异地就医直接结算越来越便捷的背后，是强大的医保信息系统支撑。截至2025年6月底，全国 超过12.36亿人开通使用医保码，医保码日均结算超过1450万人次，就医买药实现扫码直接结算，医保 政务服务线上可办率从2020年的55%增长至2024年的92%。 与此同时，门诊慢特病跨省异地就医直接结算也在"扩围"。2024年，在高血压、糖尿病等5种门诊 慢特病的基础上，新增慢性阻塞性肺疾病、类风湿关节炎、冠心病、病毒性肝炎和强直性脊柱炎5种门 诊慢特病，进行跨省直接结算。 来自河北廊坊的参保居民刘女士是这项政策的受益者。患有强直性脊柱炎的她长期在北京进行治 疗，治疗所需的司库奇尤单抗注射液每支87 ...

新华社北京8月3日电 题：动动手指就搞定——医保跨省异地就医为参保人保驾护航 新华社记者徐鹏航、彭韵佳 "以前报销需要拿着一摞发票回老家，现在刷医保卡就能直接在医院报销，方便多了！"河南居民窦女士 退休后长期随子女居住在北京，随着医保跨省异地就医直接结算的推开，以前往往需要几周的报销流 程，现在几秒钟就可以完成，还不用自己垫付资金。 窦女士的体验并非个例。跨省异地就医直接结算，正在给越来越多的参保人带来实实在在的便利。 跨省异地就医直接结算适用于跨省异地长期居住人员和跨省临时外出就医人员，参保人线上备案后，即 可按照"就医地目录，参保地政策"享受直接结算。国家医保局数据显示，目前全国跨省联网定点医药机 构达64.4万家，"十四五"期间，跨省异地就医直接结算服务超5亿人次，减少群众垫付超5500亿元。 "从备案到报销，都不用从上海跑回福州，也不需要邮寄材料，在手机上操作就可以了。"80多岁的翟先 生退休后长期跟随儿子居住在上海，此前因骨折在上海住院。住院期间，家属通过手机登录闽政通App 的"异地就医备案智能批"服务，系统自动审核秒批。 与此同时，门诊慢特病跨省异地就医直接结算也在"扩围"。2024年，在高血压 ...

Core Viewpoint - The company has made significant changes in its fundamentals since its listing two years ago, highlighted by a licensing agreement with Cullinan Therapeutics for the GR1803 dual antibody, which could yield over $712 million in total payments and revenue sharing [1][2][3]. Group 1: Licensing Agreement and Financial Implications - The licensing agreement with Cullinan Therapeutics grants them global rights for GR1803 outside of China, while the company retains rights within China [2][3]. - The agreement includes an upfront payment of $20 million and potential milestone payments of up to $692 million, along with revenue sharing, totaling over $712 million [1][3]. - The GR1803 injection is currently in Phase II clinical trials and is aimed at treating relapsed/refractory multiple myeloma, with promising early clinical data showing an overall response rate of 85% [3]. Group 2: Product Commercialization and Market Challenges - The company’s first commercialized product, Selecitinib (IL-17A monoclonal antibody), achieved sales of 30 million yuan after receiving approval for psoriasis treatment, but missed the opportunity for insurance reimbursement negotiations [1][6]. - The company reported a significant revenue increase of 2384.1% year-on-year, reaching 30.09 million yuan, but still faced a net loss of 797 million yuan [6]. - The company is actively working to negotiate for Selecitinib's inclusion in the insurance reimbursement list to enhance market penetration and sales volume [6][7]. Group 3: Future Strategies and Market Environment - The company plans to adopt a dual strategy for future growth, utilizing a sales outsourcing model domestically while pursuing early licensing agreements internationally [4]. - The innovative drug market is experiencing favorable conditions, with a surge in business development activities, as evidenced by a total of $45.5 billion in domestic innovative drug business development in the first five months of 2025 [4][7]. - The company anticipates that profitability may not be achieved until 2027, despite plans for two additional product launches in the future [7].

Core Viewpoint - New Nuo Wei (300765.SZ) announced the termination of its application for the acquisition of Shiyao Chuangxin Pharmaceutical Co., Ltd. and the associated fundraising, ending a 15-month effort for a significant restructuring deal worth 7.6 billion yuan [2][3]. Group 1: Termination of Acquisition - The termination was due to changes in the pharmaceutical industry and capital market environment since the initial planning of the restructuring, leading to a decision made in the interest of long-term shareholder benefits [2][3]. - The market reacted rationally to the termination, influenced by factors such as stock price fluctuations, increasing performance burdens, and declining acquisition targets [2][3]. Group 2: Financial Performance and Challenges - New Nuo Wei's revenue and profit have been declining, with a 21.98% year-on-year decrease in revenue to 1.981 billion yuan and an 87.63% drop in net profit to 54 million yuan in 2024 [8]. - The company's core revenue from functional foods and raw materials fell by 24.90% to 1.84 billion yuan, while the biopharmaceutical sector contributed only 87.8 million yuan, despite a 153.0% increase [10]. Group 3: Acquisition Details and Valuation - The acquisition target, Shiyao Baike, has a core product, Jinyouli, which is facing growth challenges, with a significant reliance on a single product and limited growth potential [4][7]. - The valuation for Shiyao Baike was set at 7.622 billion yuan, representing a 78.25% premium over its book value of 4.276 billion yuan, raising concerns about the high price for low-growth assets [6][7]. Group 4: R&D and Future Prospects - New Nuo Wei's R&D expenses increased by 25.44% to 842 million yuan in 2024, primarily due to the inclusion of Shiji Biological's R&D costs, indicating a significant financial burden [10][11]. - The company is under pressure from negative cash flows, with net cash flow from operating activities at -1.235 billion yuan in 2024 and -87 million yuan in the first quarter of 2025 [12][13].